ArticleJournal of ovarian research2026
Impact of anti-Müllerian hormone on pregnancy outcomes in in vitro maturation: a retrospective cohort study.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundIn vitro maturation (IVM) presents a potential alternative to conventional IVF for special subgroups of infertile couples. Anti-Müllerian Hormone (AMH) is widely regarded as the most robust biomarker for assessing ovarian reserve. However, the relationship between AMH and subsequent pregnancy success rates following IVM remains poorly characterized.
designThis was a retrospective cohort study. Infertile patients undergoing IVM treatment at Peking University Third Hospital Reproductive Medicine Center between January 2016 and June 2024. Participants were stratified by AMH (ng/ml) quartiles: Group A (1 < AMH ≤ 7.77, n = 99), B (7.77 < AMH ≤ 11.91, n = 98), C (11.91 < AMH ≤ 17.53, n = 100), and D (AMH > 17.53, n = 96). The primary outcome was cumulative live birth rate.
resultsWhile baseline characteristics (age, BMI, infertility duration/type, FSH) were comparable across groups, Group D demonstrated significantly higher immature oocyte yield (P < 0.001), and embryological parameters (transferable/high-quality embryos: P < 0.001) versus other groups. Paradoxically, Group A achieved superior clinical outcomes, including: cumulative live birth rate (48.8% vs. 29.1% vs. 37.7% vs. 21.6%, P = 0.009), cumulative clinical pregnancy rate (67.4% vs. 40.0% vs. 42.6% vs. 36.1%, P = 0.006), and clinical pregnancy rate (68.4% vs. 39.1% vs. 44.4% vs. 37.5%, P = 0.015). Multivariate analysis also indicated that excessively high AMH levels (> 17.53ng/ml) may be related to reduced clinical pregnancy rate compared to low AMH levels (OR = 0.281, 95% CI: 0.108–0.728, P = 0.009). No significant differences emerged between fresh versus frozen-thawed transfers.
conclusionElevated AMH levels (> 17.53ng/ml) predict enhanced follicular recruitment but paradoxically associate with diminished reproductive success compared to moderate AMH levels (1 < AMH ≤ 7.77 ng/ml) in IVM cycles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.